BOX 5-1

Martek’s Path to Successa

  • University of MD—Incubator—Taps—1985.

  • Venture Capital—1986.

  • SBIRs: NIH, NSF, DoE—1980s & 1990s.

  • More Venture Capital—1989 & 1990s.

  • Maryland Industrial Partnerships—MIPS—1980s & 1990s.

  • Infant Formula Licensees—1990s.

  • Public Market Finance—1993 IPO.

  • Limited Sales—1990s.

  • Secondary Public Offerings—1990s.

  • Sales Sky Rocket—2000s.

  • Profitable in Q4 2003.

  • Major Expansion of Plants.

  

aSlide presentation by Pete Linsert, “The Martek Experience,” at National Research Council, Accelerating Innovation 2005 Conference, Washington, DC, October 19, 2005.

rebates. Licensees include Mead Johnson Nutritionals, Nestle, Abbott Laboratories, Wyeth and Royal Numico. Licensees now sell infant formula products containing Martek ingredients in over 70 countries. In 2006 and 2007, Martek signed multiyear sole source agreements with Abbott Laboratories and Mead Johnson to provide proprietary ingredients for infant formula, a core business of Martek.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement